PepVax, Inc. is an early-stage biotechnology company developing a DNA-based drug delivery and development platform. Our novel DNA plasmid delivery system takes a simplified method to delivery and our “Trojan Horse” approach uses the patient’s own cells to manufacture the required proteins, T-cells and antibodies inside the patient (Intusic™) for cancers, infectious and genetic diseases. PepVax’s management team brings with it the ability to raise necessary funding, design in vitro trials in coordination with our outsourced partners, monitor the trials, and develop new technologies through cutting-edge research and development. Members of the management team have experience in setting up the necessary infrastructure for early-stage companies that will ultimately make them successful. Manufacturing cell therapies, DNA, RNA and proteins ex vivo have always been a problem, especially in scale up and cost. The process takes weeks and in the case of cell therapies, it is very painful for the patient. With administration of externally manufactured drugs of these types, there are also strong possibilities for anti-drug-antibodies (ADAs) or over-acting immune responses leading to potential autoimmune reactions like cytokine storms. Our SMARTmid™ Vector is designed to take manufacturing from outside the patient to inside the patient, using the patient's own cells to manufacture the necessary protein-, DNA- and RNA-based treatments. It is a fully synthetic method for producing plasmid vector particles for mammalian cell transduction and is a powerful template in which to build a drug delivery platform. We are looking at academics and small biotechnology companies working on new NAA drugs as our first customers. We plan to establish collaborations and licensing agreements to develop the drugs on our delivery platform, which will create early licensing revenues and a pipeline for future revenue through milestone payments and royalties.